Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
XENON XE 133-V.S.S. is an inhaled radioactive xenon gas approved in 1976 for pulmonary ventilation imaging and diagnosis. It is a diagnostic agent used to assess lung function and detect ventilation defects in patients with suspected pulmonary disease. The mechanism relies on xenon-133's radioactive properties to visualize regional ventilation patterns via nuclear imaging.
As a near-end-of-life diagnostic imaging agent facing moderate competitive pressure, the brand team is likely operating in maintenance mode with minimal headcount expansion and focus on operational efficiency.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
With zero linked job postings and LOE approaching, XENON XE 133-V.S.S. offers minimal career development opportunities within GE HealthCare. Professionals joining this product should expect stable but non-growth roles focused on compliance, maintenance, and operational efficiency rather than innovation or team expansion.
Worked on XENON XE 133-V.S.S. at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.